MedTrace Logo

Contraceptive Pathway and Contraception Continuation Rates

NCT03925116 · Status: SUSPENDED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2022-05-06

No results posted yet for this study

Summary

Women seeking contraception will be randomized to "usual care" or to a "Contraceptive Pathway"

Conditions

  • Contraceptive Usage

Interventions

OTHER

COntraceptive pathway

alternative way of aiding patients in deciding contraception method

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Rutgers, The State University of New Jersey

    lead OTHER

Principal Investigators

  • Adrian C Balica, MD · Rutgers Robert Wood Johnson Medical School

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-03
Primary Completion
2024-06-30
Completion
2024-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03925116 on ClinicalTrials.gov